22227-55-0

Usage

Uses

Used in Pharmaceutical Industry:
2-NITRO-4-TRIFLUOROMETHYLBENZAMIDE 97 is utilized as a building block for the development of pharmaceutical drugs. Its unique structure contributes to the synthesis of various organic compounds that can be further used in the creation of new medications.
Used in Agrochemical Industry:
In the agrochemical sector, 2-NITRO-4-TRIFLUOROMETHYLBENZAMIDE 97 serves as a key component in the synthesis of agricultural chemicals. Its properties allow for the development of compounds that can be used in crop protection and other agricultural applications.
Used as a Reagent in Chemical Research and Development:
2-NITRO-4-TRIFLUOROMETHYLBENZAMIDE 97 is also employed as a reagent in chemical research and development. Its high purity and unique chemical properties make it an essential tool for conducting experiments and advancing scientific understanding in various chemical fields.

InChI:InChI=1/C8H5F3N2O3/c9-8(10,11)4-1-2-5(7(12)14)6(3-4)13(15)16/h1-3H,(H2,12,14)

Upstream product

• 778-94-9 2-nitro-4-trifluoromethyl-benzonitrile 

Downstream Products

• 923945-95-3 2-nitro-4-trifluoromethyl-thiobenzamide 
• 228418-45-9 methyl 2-nitro-4-trifluoromethylbenzoate 
• 713-41-7 2-amino-4-(trifluoromethyl)benzamide 

Relevant academic research and scientific papers

Preparation method of methyl 2-nitryl-4-trifluoromethyl benzoate

The invention discloses a preparation method of methyl 2-nitryl-4-trifluoromethyl benzoate, belongs to the technical field of organic synthesis, and solves the technical problem that a new method forpreparing the methyl 2-nitryl-4-trifluoromethyl benzoate is provided. The method comprises the following steps: performing alkali catalytic or acid catalytic hydrolysis on 2-nitryl-4-trifluoromethyl benzonitrile to prepare 2-nitryl-4-trifluoromethyl phenyl methyl amide; mixing the 2-nitryl-4-trifluoromethyl phenyl methyl amide with a sulfuric acid-methanol solution and performing alcoholysis reaction to obtain the methyl 2-nitryl-4-trifluoromethyl benzoate. The method disclosed by the invention has the advantages of mild reaction conditions and simple post-processing; moreover, the high-puritymethyl 2-nitryl-4-trifluoromethyl benzoate can be obtained in a form of high yield, and realization of industrial production is facilitated.

MACROCYCLIC INHIBITORS OF HEPATITIS C VIRUS

Inhibitors of HCV replication of formula (I) and the N-oxides, salts, or stereoisomers thereof, wherein each dashed line (represented by ------) represents an optional double bond; X is N, CH and where X bears a double bond it is C; R1 is -OR6, -NH-SO2R7; R2 is hydrogen, and where X is C or CH, R2 may also be C1-6alkyl; R3 is hydrogen, C1-6alkyl, C1-6alkoxyC1-6alkyl, or C3-7cycloalkyl; n is 3, 4, 5, or 6; R4 and R5 independently from one another are hydrogen, halo, hydroxy, nitro, cyano, carboxyl, C1-6alkyl, C1-6alkoxy, C1-6alkoxyC1-6alkyl, C1-6alkylcarbonyl, C1-6alkoxy- carbonyl, amino, azido, mercapto, C1-6alkylthio, polyhaloC1-6alkyl, aryl or Het; W is aryl or Het; R6 is hydrogen; aryl; Het; C3-7cycloalkyl optionally substituted with C1-6alkyl; or C1-6alkyl optionally substituted with C3-7cycloalkyl, aryl or with Het; R7 is aryl; Het; C3-7cycloalkyl optionally substituted with C1-6alkyl; or C1-6alkyl optionally substituted with C3-7cycloalkyl, aryl or with Het; aryl is phenyl or naphthyl, each optionally substituted with 1-3 substituents; Het is a 5 or 6 membered saturated, partially unsaturated or completely unsaturated heterocyclic ring containing 1 - 4 heteroatoms each independently selected from N, O or S, and optionally substituted with 1 -3 substituents; pharmaceutical compositions containing compounds (I) and processes for preparing compounds (I). Bioavailable combinations of the inhibitors of HCV of formula (I) with ritonavir are also provided.

CAPSAICIN RECEPTOR AGONISTS

Capsaicin receptor agonists are provided. Such compounds are ligands that may be used to modulate VRl activity in vivo or in vitro, and are particularly useful in the treatment of conditions responsive to capsaicin receptor activation in humans, domesticated companion animals and livestock animals. Pharmaceutical compositions and methods for using them to treat such disorders are provided, as are methods for using such ligands for receptor localization studies.